Showing 3871-3880 of 5646 results for "".
- Humonix Biosciences Launches 3D Human Tissue Modelhttps://modernod.com/news/specialty-pharmaceutical-research-company-humonix-biosciences-launches-3d-human-tissue-model/2481864/Humonix Biosciences has developed a new 3D human tissue model called the retinal vascular dysfunction model. Humonix’s new model is a physiologically relevant 3D model of the blood-retinal barrier. This model expresses key physiological and biological characteristics, providing a platf
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Orbis International Teams Up with the Alcon Foundation and OMEGA to Improve Eye Care in Zambiahttps://modernod.com/news/orbis-international-teams-up-with-the-alcon-foundation-and-omega-to-improve-eye-care-in-zambia/2481851/Global eye care nonprofit Orbis International is kicking off a surgical training program in Zambia&nb
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- OcuCell Announces Funding from the Georgia Eye Bankhttps://modernod.com/news/ocucell-announces-funding-from-the-georgia-eye-bank/2481845/OcuCell, a provider of ocular cell therapy, announce funding from the Georgia Eye Bank. Founded in 1961, Georgia Eye Bank has provided over 60,000 corneas for transplant and is dedicated to improving vision and lives through transplantation of ocular tissue and cells. Fin
- Apellis Receives Permanent J-Code for GA Drug Syfovrehttps://modernod.com/news/apellis-receives-permanent-j-code-for-ga-drug-syfovre/2481844/The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a permanent and product-specific J-code (J2781) for Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection), the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code f